Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases

J Clin Exp Hematop. 2024;64(2):152-155. doi: 10.3960/jslrt.24014.

Authors

Masuho Saburi¹, Takumi Nishikawa¹, Yasuhiko Miyazaki¹, Kazuhiro Kohno², Masanori Sakata³, Kazuki Okuhiro³, Toshiyuki Nakayama², Eiichi Ohtsuka¹, Masao Ogata³

Affiliations

¹ Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
² Department of Hematology, Oita Kouseiren Tsurumi Hospital, Oita, Japan.
³ Department of Hematology, Oita University Hospital, Oita, Japan.

No abstract available

Keywords: Japanese; chronic lymphocytic leukemia; rituximab; small lymphocytic lymphoma; venetoclax.

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
East Asian People
Female
Humans
Japan
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / mortality
Male
Middle Aged
Retrospective Studies
Rituximab* / administration & dosage
Rituximab* / therapeutic use
Sulfonamides* / administration & dosage
Sulfonamides* / therapeutic use
Treatment Outcome

Substances

Sulfonamides
venetoclax
Rituximab
Bridged Bicyclo Compounds, Heterocyclic